BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 8549169)

  • 1. Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas.
    Johansson L; Lindén CJ
    Chest; 1996 Jan; 109(1):109-14. PubMed ID: 8549169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical differentiation of sarcomatoid mesotheliomas from other spindle cell neoplasms.
    Cagle PT; Truong LD; Roggli VL; Greenberg SD
    Am J Clin Pathol; 1989 Nov; 92(5):566-71. PubMed ID: 2479255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study.
    Lucas DR; Pass HI; Madan SK; Adsay NV; Wali A; Tabaczka P; Lonardo F
    Histopathology; 2003 Mar; 42(3):270-9. PubMed ID: 12605647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas.
    Prabhakaran S; Hocking A; Kim C; Hussey M; Klebe S
    Hum Pathol; 2020 Nov; 105():1-8. PubMed ID: 32888937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma.
    Wirth PR; Legier J; Wright GL
    Cancer; 1991 Feb; 67(3):655-62. PubMed ID: 1702354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
    Galateau Salle F; Le Stang N; Nicholson AG; Pissaloux D; Churg A; Klebe S; Roggli VL; Tazelaar HD; Vignaud JM; Attanoos R; Beasley MB; Begueret H; Capron F; Chirieac L; Copin MC; Dacic S; Danel C; Foulet-Roge A; Gibbs A; Giusiano-Courcambeck S; Hiroshima K; Hofman V; Husain AN; Kerr K; Marchevsky A; Nabeshima K; Picquenot JM; Rouquette I; Sagan C; Sauter JL; Thivolet F; Travis WD; Tsao MS; Weynand B; Damiola F; Scherpereel A; Pairon JC; Lantuejoul S; Rusch V; Girard N
    J Thorac Oncol; 2018 Aug; 13(8):1189-1203. PubMed ID: 29723687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unusual intraparenchymal growth patterns of malignant pleural mesothelioma.
    Nind NR; Attanoos RL; Gibbs AR
    Histopathology; 2003 Feb; 42(2):150-5. PubMed ID: 12558747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.
    Marchevsky AM; LeStang N; Hiroshima K; Pelosi G; Attanoos R; Churg A; Chirieac L; Dacic S; Husain A; Khoor A; Klebe S; Lantuejoul S; Roggli V; Vignaud JM; Weynard B; Sauter J; Henderson D; Nabeshima K; Galateau-Salle F
    Hum Pathol; 2017 Sep; 67():160-168. PubMed ID: 28782639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
    Capkova L; Koubkova L; Kodet R
    Neoplasma; 2014; 61(2):161-9. PubMed ID: 24471939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma.
    Kadota K; Suzuki K; Sima CS; Rusch VW; Adusumilli PS; Travis WD
    J Thorac Oncol; 2011 May; 6(5):896-904. PubMed ID: 21358344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent expression of conventional endothelial markers in pleural mesothelioma: usefulness of claudin-5 as well as combined traditional markers to distinguish mesothelioma from angiosarcoma.
    Nakashima Y; Inamura K; Ninomiya H; Okumura S; Mun M; Kirimura S; Kobayashi M; Okubo K; Ishikawa Y
    Lung Cancer; 2020 Oct; 148():20-27. PubMed ID: 32777673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma.
    Alchami FS; Attanoos RL; Bamber AR
    J Clin Pathol; 2017 Feb; 70(2):179-182. PubMed ID: 27798081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
    Muller S; Victoria Lai W; Adusumilli PS; Desmeules P; Frosina D; Jungbluth A; Ni A; Eguchi T; Travis WD; Ladanyi M; Zauderer MG; Sauter JL
    Mod Pathol; 2020 Feb; 33(2):303-311. PubMed ID: 31537897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The comparative accuracy of different pleural biopsy techniques in the diagnosis of malignant mesothelioma.
    Attanoos RL; Gibbs AR
    Histopathology; 2008 Sep; 53(3):340-4. PubMed ID: 18647189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathology of mesothelioma.
    Corson JM
    Thorac Surg Clin; 2004 Nov; 14(4):447-60. PubMed ID: 15559051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Localized and diffuse mesotheliomas of the genital tract and peritoneum in women. A clinicopathologic study of nineteen true mesothelial neoplasms, other than adenomatoid tumors, multicystic mesotheliomas, and localized fibrous tumors.
    Goldblum J; Hart WR
    Am J Surg Pathol; 1995 Oct; 19(10):1124-37. PubMed ID: 7573671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers.
    Trupiano JK; Geisinger KR; Willingham MC; Manders P; Zbieranski N; Case D; Levine EA
    Mod Pathol; 2004 Apr; 17(4):476-81. PubMed ID: 14976533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology.
    Kadota K; Kachala SS; Nitadori J; Suzuki K; Dunphy MP; Sima CS; Travis WD; Rusch VW; Adusumilli PS
    J Thorac Oncol; 2012 Jul; 7(7):1192-7. PubMed ID: 22617244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
    Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
    Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Morphological diagnostics of malignant pleural mesothelioma].
    Junker K; Müller KM
    Pathologe; 2014 Nov; 35(6):586-90. PubMed ID: 25304423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.